Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation

被引：0

作者：

Deng, Lei ^{[1
]}

Yu, Xiaolin ^{[1
]}

Song, Xiaocheng ^{[1
]}

Guan, Rui ^{[1
]}

Li, Wenjun ^{[1
]}

Hou, Yixi ^{[1
]}

Shao, Yan ^{[1
]}

Zhao, Yuerong ^{[1
]}

Wang, Jing ^{[1
]}

Liu, Yue ^{[1
]}

Xiao, Qianqian ^{[1
]}

Xin, Bo ^{[1
]}

Zhou, Fang ^{[1
]}

机构：

[1] 960th Hosp Chinese Peoples Liberat Army Joint Logi, Dept Hematol, 46 Shifan Rd, Jinan, Peoples R China

来源：

CYTOTHERAPY | 2024年 / 26卷 / 11期

关键词：

acute lymphoblastic leukemia; chimeric antigen receptor T -cell; graft-versus-host disease; hematopoietic stem cell transplantation; platelet recovery; VERSUS-HOST-DISEASE; THERAPY; ADULTS; CD19; RECOVERY; GVHD;

D O I：

10.1016/j.jcyt.2024.05.021

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

The one-year survival rate for patients experiencing a relapse of B-cell acute lymphocytic leukemia (B-ALL) following hematopoietic stem cell transplantation (HSCT) is approximately 30%. Patients experiencing a relapse after allogeneic HSCT frequently encounter difficulties in obtaining autologous CAR-T products. We conducted a study involving 14 patients who received donor-derived CAR-T therapy for relapsed B-ALL following HSCT between August 2019 and May 2023 in our center. The results revealed a CR/CRi rate of 78.6% (11/14), a GVHD rate of 21.4% (3/14), and a 1-year overall survival (OS) rate of 56%. Decreased bone marrow donor cell chimerism in 9 patients recovered after CAR-T therapy. The main causes of death were disease progression and infection. Further analysis showed that GVHD (HR 7.224,95% CI 1.42-36.82, P = 0.017) and platelet recovery at 30 days (HR 6.807, 95% CI 1.61-28.83, P = 0.009) are significantly associated with OS after CAR-T therapy. Based on the findings, we conclude that donor-derived CAR-T cells are effective in treating relapsed B-ALL patients following HSCT. Additionally, GVHD and poor platelet recovery impact OS, but further verification with a larger sample size is needed. (c) 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

引用

页码：1301 / 1307

页数：7

共 46 条

[1] Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD [J].

Alho, Ana C. ;

Kim, Haesook T. ;

Chammas, Marie J. ;

Reynolds, Carol G. ;

Matos, Tiago R. ;

Forcade, Edouard ;

Whangbo, Jennifer ;

Nikiforow, Sarah ;

Cutler, Corey S. ;

Koreth, John ;

Ho, Vincent T. ;

Armand, Philippe ;

Antin, Joseph H. ;

Alyea, Edwin P. ;

Lacerda, Joao F. ;

Soiffer, Robert J. ;

Ritz, Jerome .

BLOOD, 2016, 127 (05) :646-657

[2] Toxicities of chimeric antigen receptor T cells: recognition and management [J].

Brudno, Jennifer N. ;

Kochenderfer, James N. .

BLOOD, 2016, 127 (26) :3321-3330

[3] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease [J].

Brudno, Jennifer N. ;

Somerville, Robert P. T. ;

Shi, Victoria ;

Rose, Jeremy J. ;

Halverson, David C. ;

Fowler, Daniel H. ;

Gea-Banacloche, Juan C. ;

Pavletic, Steven Z. ;

Hickstein, Dennis D. ;

Lu, Tangying L. ;

Feldman, Steven A. ;

Iwamoto, Alexander T. ;

Kurlander, Roger ;

Maric, Irina ;

Goy, Andre ;

Hansen, Brenna G. ;

Wilder, Jennifer S. ;

Blacklock-Schuver, Bazetta ;

Hakim, Frances T. ;

Rosenberg, Steven A. ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1112-+

[4] Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis [J].

Chen, Sifei ;

Zhang, Yuchen ;

Fang, Chenglong ;

Zhang, Nianqin ;

Wang, Yu ;

Chen, Runkai ;

Li, Yuhua ;

Tu, Sanfang .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 179

[5] CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial [J].

Cordoba, Shaun ;

Onuoha, Shimobi ;

Thomas, Simon ;

Pignataro, Daniela Soriano ;

Hough, Rachael ;

Ghorashian, Sara ;

Vora, Ajay ;

Bonney, Denise ;

Veys, Paul ;

Rao, Kanchan ;

Lucchini, Giovanna ;

Chiesa, Robert ;

Chu, Jan ;

Clark, Liz ;

Fung, Mei Mei ;

Smith, Koval ;

Peticone, Carlotta ;

Al-Hajj, Muhammad ;

Baldan, Vania ;

Ferrari, Mathieu ;

Srivastava, Saket ;

Jha, Ram ;

Vargas, Frederick Arce ;

Duffy, Kevin ;

Day, William ;

Virgo, Paul ;

Wheeler, Lucy ;

Hancock, Jeremy ;

Farzaneh, Farzin ;

Domning, Sabine ;

Zhang, Yiyun ;

Khokhar, Nushmia Z. ;

Peddareddigari, Vijay G. R. ;

Wynn, Robert ;

Pule, Martin ;

Amrolia, Persis J. .

NATURE MEDICINE, 2021, 27 (10) :1797-+

[6] Flow cytometry-based methods for studying signaling in human CD4+CD25+FOXP3+ T regulatory cells [J].

Crellin, Natasha K. ;

Garcia, Rosa V. ;

Levings, Megan K. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2007, 324 (1-2) :92-104

[7] Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children [J].

Dahlberg, Ann ;

Leisenring, Wendy ;

Bleakley, Marie ;

Meshinchi, Soheil ;

Baker, K. Scott ;

Summers, Corinne ;

Hadland, Brandon ;

Delaney, Colleen ;

Mallhi, Kanwaldeep ;

Burroughs, Lauri ;

Carpenter, Paul ;

Woolfrey, Ann .

BONE MARROW TRANSPLANTATION, 2019, 54 (08) :1337-1345

[8] Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia [J].

Dourthe, Marie-Emilie ;

Rabian, Florence ;

Yakouben, Karima ;

Chevillon, Florian ;

Cabannes-Hamy, Aurelie ;

Mechinaud, Francoise ;

Grain, Audrey ;

Chaillou, Delphine ;

Rahal, Ilhem ;

Caillat-Zucman, Sophie ;

Lesprit, Emmanuelle ;

Naudin, Jerome ;

Roupret-Serzec, Julie ;

Parquet, Nathalie ;

Brignier, Anne ;

Guerin-El Khourouj, Valerie ;

Lainey, Elodie ;

Caye-Eude, Aurelie ;

Cave, Helene ;

Clappier, Emmanuelle ;

Mathis, Stephanie ;

Azoulay, Elie ;

Dallel, Jean Hugues ;

Dhedin, Nathalie ;

Madelaine, Isabelle ;

Larghero, Jerome ;

Boissel, Nicolas ;

Baruchel, Andre .

LEUKEMIA, 2021, 35 (12) :3383-3393

[9] CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation [J].

Edinger, M ;

Hoffmann, P ;

Ermann, J ;

Drago, K ;

Fathman, CG ;

Strober, S ;

Negrin, RS .

NATURE MEDICINE, 2003, 9 (09) :1144-1150

[10] Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study [J].

Fielding, Adele K. ;

Richards, Susan M. ;

Chopra, Rajesh ;

Lazarus, Hillard M. ;

Litzow, Mark R. ;

Buck, Georgina ;

Durrant, I. Jill ;

Luger, Selina M. ;

Marks, David I. ;

Franklin, Ian M. ;

McMillan, Andrew K. ;

Tallman, Martin S. ;

Rowe, Jacob M. ;

Goldstone, Anthony H. .

BLOOD, 2007, 109 (03) :944-950

← 1 2 3 4 5 →